<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>Chapter 7 Renal | Vascular Surgery Board Review</title>
  <meta name="description" content="This is an ebook version of board review content produced for Audible Bleeding: The Vascular Surgery Podcast" />
  <meta name="generator" content="bookdown 0.24 and GitBook 2.6.7" />

  <meta property="og:title" content="Chapter 7 Renal | Vascular Surgery Board Review" />
  <meta property="og:type" content="book" />
  <meta property="og:url" content="https://adam-mdmph.github.io/VS-Board-Review/" />
  
  <meta property="og:description" content="This is an ebook version of board review content produced for Audible Bleeding: The Vascular Surgery Podcast" />
  <meta name="github-repo" content="https://github.com/adam-mdmph/VS-Board-Review" />

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Chapter 7 Renal | Vascular Surgery Board Review" />
  
  <meta name="twitter:description" content="This is an ebook version of board review content produced for Audible Bleeding: The Vascular Surgery Podcast" />
  

<meta name="author" content="Editors: Adam Johnson, MD, MPH; Matt Smith, MD, PhD; and Audible Bleeding" />


<meta name="date" content="2022-02-13" />

  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="mesenteric-disease.html"/>
<link rel="next" href="thoracic-aorta.html"/>
<script src="libs/header-attrs-2.11/header-attrs.js"></script>
<script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/fuse.js@6.4.6/dist/fuse.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />








<link href="libs/anchor-sections-1.0.1/anchor-sections.css" rel="stylesheet" />
<script src="libs/anchor-sections-1.0.1/anchor-sections.js"></script>



<style type="text/css">
/* Used with Pandoc 2.11+ new --citeproc when CSL is used */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>

<link rel="stylesheet" href="style.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="./">VS Board Review</a></li>

<li class="divider"></li>
<li class="chapter" data-level="1" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i><b>1</b> About</a>
<ul>
<li class="chapter" data-level="1.1" data-path="index.html"><a href="index.html#usage"><i class="fa fa-check"></i><b>1.1</b> Usage</a></li>
<li class="chapter" data-level="1.2" data-path="index.html"><a href="index.html#comments-questions-or-contributions"><i class="fa fa-check"></i><b>1.2</b> Comments, Questions or Contributions</a></li>
</ul></li>
<li class="chapter" data-level="2" data-path="cerebrovascular.html"><a href="cerebrovascular.html"><i class="fa fa-check"></i><b>2</b> Cerebrovascular</a>
<ul>
<li class="chapter" data-level="2.1" data-path="cerebrovascular.html"><a href="cerebrovascular.html#available-guidelines"><i class="fa fa-check"></i><b>2.1</b> Available Guidelines</a></li>
<li class="chapter" data-level="2.2" data-path="cerebrovascular.html"><a href="cerebrovascular.html#presentation-and-diagnosis"><i class="fa fa-check"></i><b>2.2</b> Presentation and Diagnosis</a></li>
<li class="chapter" data-level="2.3" data-path="cerebrovascular.html"><a href="cerebrovascular.html#management"><i class="fa fa-check"></i><b>2.3</b> Management</a>
<ul>
<li class="chapter" data-level="2.3.1" data-path="cerebrovascular.html"><a href="cerebrovascular.html#optimal-medical-therapy"><i class="fa fa-check"></i><b>2.3.1</b> <strong>Optimal medical therapy</strong></a></li>
<li class="chapter" data-level="2.3.2" data-path="cerebrovascular.html"><a href="cerebrovascular.html#carotid-endarterectomy"><i class="fa fa-check"></i><b>2.3.2</b> <strong>Carotid endarterectomy</strong></a></li>
<li class="chapter" data-level="2.3.3" data-path="cerebrovascular.html"><a href="cerebrovascular.html#carotid-artery-stenting"><i class="fa fa-check"></i><b>2.3.3</b> Carotid Artery Stenting</a></li>
<li class="chapter" data-level="2.3.4" data-path="cerebrovascular.html"><a href="cerebrovascular.html#management-of-uncommon-disease-presentations"><i class="fa fa-check"></i><b>2.3.4</b> Management of uncommon disease presentations</a></li>
</ul></li>
<li class="chapter" data-level="2.4" data-path="cerebrovascular.html"><a href="cerebrovascular.html#prospective-trials---must-reads"><i class="fa fa-check"></i><b>2.4</b> Prospective Trials - MUST READS</a></li>
</ul></li>
<li class="chapter" data-level="3" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html"><i class="fa fa-check"></i><b>3</b> Upper Extremity and Thoracic Outlet</a>
<ul>
<li class="chapter" data-level="3.1" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#anatomy-exposure-of-vessels"><i class="fa fa-check"></i><b>3.1</b> Anatomy/ Exposure of Vessels</a></li>
<li class="chapter" data-level="3.2" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#epidemiology-etiology-and-diagnostic-evaluation"><i class="fa fa-check"></i><b>3.2</b> Epidemiology, etiology, and diagnostic evaluation</a></li>
<li class="chapter" data-level="3.3" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#operationsprocedures"><i class="fa fa-check"></i><b>3.3</b> Operations/Procedures</a></li>
<li class="chapter" data-level="3.4" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#vaso-occlusive-disease"><i class="fa fa-check"></i><b>3.4</b> Vaso-occlusive disease</a></li>
<li class="chapter" data-level="3.5" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#vasospastic-disorders"><i class="fa fa-check"></i><b>3.5</b> Vasospastic Disorders</a>
<ul>
<li class="chapter" data-level="3.5.1" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#ergotism"><i class="fa fa-check"></i><b>3.5.1</b> <strong>Ergotism</strong></a></li>
<li class="chapter" data-level="3.5.2" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#buergers-disease"><i class="fa fa-check"></i><b>3.5.2</b> <strong>Buerger’s Disease</strong></a></li>
<li class="chapter" data-level="3.5.3" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#large-artery-vasculitis"><i class="fa fa-check"></i><b>3.5.3</b> <strong>Large Artery Vasculitis</strong></a></li>
</ul></li>
<li class="chapter" data-level="3.6" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#aneurysmal-disease"><i class="fa fa-check"></i><b>3.6</b> Aneurysmal Disease</a></li>
<li class="chapter" data-level="3.7" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#occupational-vascular-disease"><i class="fa fa-check"></i><b>3.7</b> Occupational Vascular Disease</a>
<ul>
<li class="chapter" data-level="3.7.1" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#hand-arm-vibration-syndrome"><i class="fa fa-check"></i><b>3.7.1</b> Hand-Arm Vibration Syndrome </a></li>
<li class="chapter" data-level="3.7.2" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#hypothenar-hammer-syndrome"><i class="fa fa-check"></i><b>3.7.2</b> Hypothenar hammer syndrome</a></li>
<li class="chapter" data-level="3.7.3" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#environmental-exposures"><i class="fa fa-check"></i><b>3.7.3</b> Environmental Exposures</a></li>
<li class="chapter" data-level="3.7.4" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#sports-medicine"><i class="fa fa-check"></i><b>3.7.4</b> Sports Medicine</a></li>
</ul></li>
<li class="chapter" data-level="3.8" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#vascular-trauma-upper-extremity"><i class="fa fa-check"></i><b>3.8</b> Vascular Trauma-Upper Extremity</a></li>
<li class="chapter" data-level="3.9" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#compression-syndromes"><i class="fa fa-check"></i><b>3.9</b> Compression Syndromes</a>
<ul>
<li class="chapter" data-level="3.9.1" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#quadrilateral-space-syndrome"><i class="fa fa-check"></i><b>3.9.1</b> Quadrilateral space syndrome</a></li>
<li class="chapter" data-level="3.9.2" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#humeral-head-compression-of-axillary-artery"><i class="fa fa-check"></i><b>3.9.2</b> Humeral head compression of axillary artery</a></li>
</ul></li>
<li class="chapter" data-level="3.10" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#thoracic-outlet-syndrome"><i class="fa fa-check"></i><b>3.10</b> Thoracic Outlet Syndrome</a>
<ul>
<li class="chapter" data-level="3.10.1" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#anatomy"><i class="fa fa-check"></i><b>3.10.1</b> Anatomy</a></li>
<li class="chapter" data-level="3.10.2" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#diagnosis-and-evaluation"><i class="fa fa-check"></i><b>3.10.2</b> Diagnosis and Evaluation</a></li>
<li class="chapter" data-level="3.10.3" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#rib-resection-approaches"><i class="fa fa-check"></i><b>3.10.3</b> Rib Resection approaches</a></li>
<li class="chapter" data-level="3.10.4" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#vtos"><i class="fa fa-check"></i><b>3.10.4</b> vTOS</a></li>
<li class="chapter" data-level="3.10.5" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#atos"><i class="fa fa-check"></i><b>3.10.5</b> aTOS</a></li>
<li class="chapter" data-level="3.10.6" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#ntos"><i class="fa fa-check"></i><b>3.10.6</b> nTOS</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="4" data-path="abdominaliliacperipheral-aneurysms.html"><a href="abdominaliliacperipheral-aneurysms.html"><i class="fa fa-check"></i><b>4</b> Abdominal/Iliac/Peripheral Aneurysms</a>
<ul>
<li class="chapter" data-level="4.1" data-path="abdominaliliacperipheral-aneurysms.html"><a href="abdominaliliacperipheral-aneurysms.html#pathogenesis-presentation-and-risk-factors"><i class="fa fa-check"></i><b>4.1</b> Pathogenesis, presentation and risk factors</a></li>
<li class="chapter" data-level="4.2" data-path="abdominaliliacperipheral-aneurysms.html"><a href="abdominaliliacperipheral-aneurysms.html#evaluation-and-diagnosis"><i class="fa fa-check"></i><b>4.2</b> Evaluation and Diagnosis</a>
<ul>
<li class="chapter" data-level="4.2.1" data-path="abdominaliliacperipheral-aneurysms.html"><a href="abdominaliliacperipheral-aneurysms.html#imaging"><i class="fa fa-check"></i><b>4.2.1</b> Imaging</a></li>
</ul></li>
<li class="chapter" data-level="4.3" data-path="abdominaliliacperipheral-aneurysms.html"><a href="abdominaliliacperipheral-aneurysms.html#management-1"><i class="fa fa-check"></i><b>4.3</b> Management</a>
<ul>
<li class="chapter" data-level="4.3.1" data-path="abdominaliliacperipheral-aneurysms.html"><a href="abdominaliliacperipheral-aneurysms.html#evar"><i class="fa fa-check"></i><b>4.3.1</b> EVAR</a></li>
<li class="chapter" data-level="4.3.2" data-path="abdominaliliacperipheral-aneurysms.html"><a href="abdominaliliacperipheral-aneurysms.html#open-repair"><i class="fa fa-check"></i><b>4.3.2</b> Open Repair</a></li>
<li class="chapter" data-level="4.3.3" data-path="abdominaliliacperipheral-aneurysms.html"><a href="abdominaliliacperipheral-aneurysms.html#ruptured-aneurysms"><i class="fa fa-check"></i><b>4.3.3</b> Ruptured Aneurysms</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="5" data-path="lower-extremity-occlusive-disease.html"><a href="lower-extremity-occlusive-disease.html"><i class="fa fa-check"></i><b>5</b> Lower Extremity Occlusive Disease</a>
<ul>
<li class="chapter" data-level="5.1" data-path="lower-extremity-occlusive-disease.html"><a href="lower-extremity-occlusive-disease.html#pathophysiology"><i class="fa fa-check"></i><b>5.1</b> Pathophysiology</a></li>
<li class="chapter" data-level="5.2" data-path="lower-extremity-occlusive-disease.html"><a href="lower-extremity-occlusive-disease.html#intermittent-claudication"><i class="fa fa-check"></i><b>5.2</b> Intermittent Claudication</a>
<ul>
<li class="chapter" data-level="5.2.1" data-path="lower-extremity-occlusive-disease.html"><a href="lower-extremity-occlusive-disease.html#history-clinical-examination"><i class="fa fa-check"></i><b>5.2.1</b> History / Clinical Examination</a></li>
<li class="chapter" data-level="5.2.2" data-path="lower-extremity-occlusive-disease.html"><a href="lower-extremity-occlusive-disease.html#management-2"><i class="fa fa-check"></i><b>5.2.2</b> Management</a></li>
</ul></li>
<li class="chapter" data-level="5.3" data-path="lower-extremity-occlusive-disease.html"><a href="lower-extremity-occlusive-disease.html#chronic-limb-threatening-ischemia"><i class="fa fa-check"></i><b>5.3</b> Chronic Limb Threatening Ischemia</a></li>
<li class="chapter" data-level="5.4" data-path="lower-extremity-occlusive-disease.html"><a href="lower-extremity-occlusive-disease.html#acute-limb-ischemia"><i class="fa fa-check"></i><b>5.4</b> Acute Limb Ischemia</a>
<ul>
<li class="chapter" data-level="5.4.1" data-path="lower-extremity-occlusive-disease.html"><a href="lower-extremity-occlusive-disease.html#presentation-and-diangosis"><i class="fa fa-check"></i><b>5.4.1</b> Presentation and Diangosis</a></li>
<li class="chapter" data-level="5.4.2" data-path="lower-extremity-occlusive-disease.html"><a href="lower-extremity-occlusive-disease.html#management-3"><i class="fa fa-check"></i><b>5.4.2</b> Management</a></li>
<li class="chapter" data-level="5.4.3" data-path="lower-extremity-occlusive-disease.html"><a href="lower-extremity-occlusive-disease.html#compartment-syndrome"><i class="fa fa-check"></i><b>5.4.3</b> Compartment Syndrome</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="6" data-path="mesenteric-disease.html"><a href="mesenteric-disease.html"><i class="fa fa-check"></i><b>6</b> Mesenteric Disease</a>
<ul>
<li class="chapter" data-level="6.1" data-path="mesenteric-disease.html"><a href="mesenteric-disease.html#acute-mesenteric-ischemia"><i class="fa fa-check"></i><b>6.1</b> Acute Mesenteric Ischemia</a>
<ul>
<li class="chapter" data-level="6.1.1" data-path="mesenteric-disease.html"><a href="mesenteric-disease.html#presentation-and-diagnosis-1"><i class="fa fa-check"></i><b>6.1.1</b> Presentation and diagnosis</a></li>
<li class="chapter" data-level="6.1.2" data-path="mesenteric-disease.html"><a href="mesenteric-disease.html#management-4"><i class="fa fa-check"></i><b>6.1.2</b> Management</a></li>
<li class="chapter" data-level="6.1.3" data-path="mesenteric-disease.html"><a href="mesenteric-disease.html#rare-etiologies"><i class="fa fa-check"></i><b>6.1.3</b> Rare Etiologies</a></li>
</ul></li>
<li class="chapter" data-level="6.2" data-path="mesenteric-disease.html"><a href="mesenteric-disease.html#chronic-mesenteric-ischemia"><i class="fa fa-check"></i><b>6.2</b> Chronic Mesenteric Ischemia</a>
<ul>
<li class="chapter" data-level="6.2.1" data-path="mesenteric-disease.html"><a href="mesenteric-disease.html#presentation-and-diagnosis-2"><i class="fa fa-check"></i><b>6.2.1</b> Presentation and Diagnosis</a></li>
<li class="chapter" data-level="6.2.2" data-path="mesenteric-disease.html"><a href="mesenteric-disease.html#management-5"><i class="fa fa-check"></i><b>6.2.2</b> Management</a></li>
</ul></li>
<li class="chapter" data-level="6.3" data-path="mesenteric-disease.html"><a href="mesenteric-disease.html#median-arcuate-ligament-syndrome-mals"><i class="fa fa-check"></i><b>6.3</b> Median Arcuate Ligament Syndrome (MALS)</a></li>
<li class="chapter" data-level="6.4" data-path="mesenteric-disease.html"><a href="mesenteric-disease.html#sma-syndrome"><i class="fa fa-check"></i><b>6.4</b> SMA Syndrome</a></li>
</ul></li>
<li class="chapter" data-level="7" data-path="renal.html"><a href="renal.html"><i class="fa fa-check"></i><b>7</b> Renal</a>
<ul>
<li class="chapter" data-level="7.1" data-path="renal.html"><a href="renal.html#pathophysiology-1"><i class="fa fa-check"></i><b>7.1</b> Pathophysiology</a></li>
<li class="chapter" data-level="7.2" data-path="renal.html"><a href="renal.html#medical-management-and-evaluation"><i class="fa fa-check"></i><b>7.2</b> Medical Management and Evaluation</a></li>
<li class="chapter" data-level="7.3" data-path="renal.html"><a href="renal.html#operative-managment"><i class="fa fa-check"></i><b>7.3</b> Operative Managment</a>
<ul>
<li class="chapter" data-level="7.3.1" data-path="renal.html"><a href="renal.html#endovascular-therapy"><i class="fa fa-check"></i><b>7.3.1</b> Endovascular Therapy</a></li>
<li class="chapter" data-level="7.3.2" data-path="renal.html"><a href="renal.html#open-surgery"><i class="fa fa-check"></i><b>7.3.2</b> Open Surgery</a></li>
</ul></li>
<li class="chapter" data-level="7.4" data-path="renal.html"><a href="renal.html#fibromuscular-dysplasia-fmd"><i class="fa fa-check"></i><b>7.4</b> Fibromuscular Dysplasia (FMD)</a></li>
<li class="chapter" data-level="7.5" data-path="renal.html"><a href="renal.html#renal-artery-aneurysms"><i class="fa fa-check"></i><b>7.5</b> Renal Artery Aneurysms</a></li>
</ul></li>
<li class="chapter" data-level="8" data-path="thoracic-aorta.html"><a href="thoracic-aorta.html"><i class="fa fa-check"></i><b>8</b> Thoracic Aorta</a>
<ul>
<li class="chapter" data-level="8.1" data-path="thoracic-aorta.html"><a href="thoracic-aorta.html#section"><i class="fa fa-check"></i><b>8.1</b> </a></li>
</ul></li>
<li class="chapter" data-level="9" data-path="venous-disease.html"><a href="venous-disease.html"><i class="fa fa-check"></i><b>9</b> Venous Disease</a>
<ul>
<li class="chapter" data-level="9.1" data-path="venous-disease.html"><a href="venous-disease.html#section-1"><i class="fa fa-check"></i><b>9.1</b> </a></li>
</ul></li>
<li class="chapter" data-level="10" data-path="vascular-trauma.html"><a href="vascular-trauma.html"><i class="fa fa-check"></i><b>10</b> Vascular Trauma</a>
<ul>
<li class="chapter" data-level="10.1" data-path="vascular-trauma.html"><a href="vascular-trauma.html#section-2"><i class="fa fa-check"></i><b>10.1</b> </a></li>
</ul></li>
<li class="chapter" data-level="11" data-path="angioaccess.html"><a href="angioaccess.html"><i class="fa fa-check"></i><b>11</b> Angioaccess</a>
<ul>
<li class="chapter" data-level="11.1" data-path="angioaccess.html"><a href="angioaccess.html#section-3"><i class="fa fa-check"></i><b>11.1</b> </a></li>
</ul></li>
<li class="chapter" data-level="12" data-path="complications-1.html"><a href="complications-1.html"><i class="fa fa-check"></i><b>12</b> Complications</a>
<ul>
<li class="chapter" data-level="12.1" data-path="complications-1.html"><a href="complications-1.html#section-4"><i class="fa fa-check"></i><b>12.1</b> </a></li>
</ul></li>
<li class="chapter" data-level="13" data-path="amputations.html"><a href="amputations.html"><i class="fa fa-check"></i><b>13</b> Amputations</a>
<ul>
<li class="chapter" data-level="13.1" data-path="amputations.html"><a href="amputations.html#section-5"><i class="fa fa-check"></i><b>13.1</b> </a></li>
</ul></li>
<li class="chapter" data-level="14" data-path="vascular-lab.html"><a href="vascular-lab.html"><i class="fa fa-check"></i><b>14</b> Vascular Lab</a>
<ul>
<li class="chapter" data-level="14.1" data-path="vascular-lab.html"><a href="vascular-lab.html#section-6"><i class="fa fa-check"></i><b>14.1</b> </a></li>
</ul></li>
<li class="chapter" data-level="15" data-path="vascular-medicine.html"><a href="vascular-medicine.html"><i class="fa fa-check"></i><b>15</b> Vascular Medicine</a>
<ul>
<li class="chapter" data-level="15.1" data-path="vascular-medicine.html"><a href="vascular-medicine.html#section-7"><i class="fa fa-check"></i><b>15.1</b> </a></li>
</ul></li>
<li class="chapter" data-level="16" data-path="endovascular.html"><a href="endovascular.html"><i class="fa fa-check"></i><b>16</b> Endovascular</a>
<ul>
<li class="chapter" data-level="16.1" data-path="endovascular.html"><a href="endovascular.html#section-8"><i class="fa fa-check"></i><b>16.1</b> </a></li>
</ul></li>
<li class="chapter" data-level="17" data-path="applied-science.html"><a href="applied-science.html"><i class="fa fa-check"></i><b>17</b> Applied Science</a>
<ul>
<li class="chapter" data-level="17.1" data-path="applied-science.html"><a href="applied-science.html#section-9"><i class="fa fa-check"></i><b>17.1</b> </a></li>
</ul></li>
<li class="chapter" data-level="" data-path="references.html"><a href="references.html"><i class="fa fa-check"></i>References</a></li>
<li class="divider"></li>
<li><a href="https://github.com/rstudio/bookdown" target="blank">Published with bookdown</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">Vascular Surgery Board Review</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="renal" class="section level1" number="7">
<h1><span class="header-section-number">Chapter 7</span> Renal</h1>
<p><strong>29 Jun 2020:</strong> <em>Dr. Cullen McCarthy and Dr. Matthew Edwards; Wake
Forest</em></p>
<p><audio controls> <source src='https://traffic.libsyn.com/audiblebleeding/Renalvascular_take_2.mp3' type='audio/mpeg'> Your browser does not support the audio tag;  for browser support, please see:  https://www.w3schools.com/tags/tag_audio.asp </audio></p>
<div id="pathophysiology-1" class="section level2" number="7.1">
<h2><span class="header-section-number">7.1</span> Pathophysiology</h2>
<p><strong>What is renovascular hypertension?</strong></p>
<p>Hypertension as a result of progressive renal artery stenosis</p>
<ul>
<li>While renal artery stenosis is a relatively common finding in older
patients with hypertension, it’s relatively uncommon as the primary
cause of hypertension.</li>
</ul>
<p><strong>What is ischemic nephropathy?</strong></p>
<p>Decreased renal function and/or chronic kidney disease that results from
atherosclerotic renal artery stenosis due to a reduction in glomerular
filtration rate (GFR) and rise in creatine produced by any cause of
diminished renal blood flow that threatens</p>
<p><strong>Who is at risk for ischemic nephropathy?</strong></p>
<p>Renal injury can develop in anyone with a kidney or kidney region beyond
a critically stenotic artery</p>
<ul>
<li><p>Now, this is usually in patients with atherosclerotic disease, but
any flow limiting lesion—such as coarctation of the aorta,
mid-aortic syndrome, or fibromuscular dyplasia– can cause ischemic
neuropathy OR renovascular hypertension.</p></li>
<li><p>In terms of clinical practice, the prevalence of renovascular
hypertension is probably less than 1 % in patients with mild
hypertension but may be as high as 10 to 40 % in patients with acute
(even if superimposed on a preexisting elevation in blood pressure),
severe, or refractory hypertension.</p></li>
</ul>
<p><strong>That’s the best you can do, 10-40%? That’s a big window.</strong></p>
<p>Yes, and it illustrates the biggest issue we have with renovascular
disease. We know 5-22 % of patients 50 years or older who have advanced
CKD have some degree of renal artery stenosis and 23 to 54% of these
patients have bilateral renal artery disease.</p>
<ul>
<li><p>Bilateral renal arterial stenosis is associated with more widespread
atherosclerotic disease, higher serum creatinine levels, and higher
mortality than unilateral disease</p></li>
<li><p>Renal artery revascularization among patients in these studies
infrequently produced a meaningful recovery of kidney function,
which would have supported the diagnosis</p></li>
</ul>
<p><strong>So not everyone with flow limitations to their renal vascular will get
renovascular hypertension or ischemic nephropathy?</strong></p>
<p>Not at all, actually. Flow limiting lesions may be an “incidental”
finding in patients who have CKD or hypertension that is caused by a
separate disorder (eg, diabetic nephropathy and essential/primary
hypertension).</p>
<ul>
<li>Because of this, it can be very difficult to distinguish between
patient whose disease is induced by renal artery stenosis and those
who have alternative causes of CKD or renovascular hypertension.</li>
</ul>
<p><strong>So you’re telling me that we have no idea who has clinically
significant disease and who doesn’t?</strong></p>
<p>No. Fortunately there are clinical findings that suggest that
renovascular disease is an underlying cause:</p>
<ul>
<li><p>Recent or rapid development of severe hypertension.</p>
<ul>
<li>Relatively specific for renovascular hypertension and is the
strongest predictor of antihypertensive benefit from
revascularization.</li>
</ul></li>
<li><p>Severe hypertension that may be treatment resistant.</p>
<ul>
<li>Some patients with ischemic nephropathy are normotensive, which
may be due in part to a reduced cardiac output</li>
</ul></li>
<li><p>Acute rise in serum creatinine following the administration of
angiotensin-converting enzyme (ACE) inhibitors or angiotensin
receptor blockers (ARBs).</p>
<ul>
<li><p>Rise in serum creatinine is more common with agents that block
the renin-angiotensin system than with other antihypertensive
drugs because glomerular filtration rate (GFR) often depends
upon the efferent arteriolar actions of angiotensin II in this
setting.</p></li>
<li><p>More common with bilateral as compared with unilateral disease
because there is hemodynamic compromise to the entire renal
functional mass</p></li>
<li><p>This usually resolves after withdrawal of the drug.</p></li>
<li><p>Restoring the renal blood supply in such cases can recover the
ability to use these drugs for blood pressure control.</p></li>
</ul></li>
<li><p>Significant variability of serum creatinine concentration that may
be due to changes in volume status</p></li>
<li><p>A rapid rise in arterial pressure associated with sudden development
of left ventricular failure (“flash pulmonary edema”).</p>
<ul>
<li>This finding is more common with renal artery stenosis because
bilateral disease is also associated with diuretic resistance
and sympathetic adrenergic activation</li>
</ul></li>
<li><p>Deterioration of kidney function after placement of an endovascular
aortic stent graft– IATROGENIC</p></li>
</ul>
<p><strong>So it matters which kidney is affected or if it’s one or both?</strong></p>
<p>Yes, effect of the stenosis may not be clinically apparent due to
compensatory function of the unaffected contralateral kidney</p>
<ul>
<li><p>Most cases of renal artery stenosis affect one side much more than
the other; one kidney is affected with the second kidney being
essentially normal, hence the designation “unilateral” disease.</p></li>
<li><p>Patients who are diagnosed with ischemic nephropathy usually have
high-grade stenosis of both renal arteries or stenosis to a solitary
functioning kidney.</p>
<ul>
<li>It is this subpopulation of the disease that merits specific
consideration because of its additional contribution to fluid
retention, loss of kidney function, and congestive heart
failure.</li>
</ul></li>
</ul>
<p><strong>What are the pathophysiological mechanisms at play here?</strong></p>
<p>Like we said, first you need a flow limitation. We mentioned several,
but by in large There are two major causes of renal artery stenosis:</p>
<ol style="list-style-type: decimal">
<li><p>Atherosclerosis – you’ll generally see this in patients over 45
years old, likely with known PVD/CAD—though it can occur as an
isolated renal lesion—usually involving the aortic orifice or the
proximal main renal artery.</p></li>
<li><p>Fibromuscular dysplasia – These patients are most often women under
the age of 50 years and typically involves the mid- or distal main
renal artery or the intrarenal branches.</p>
<ul>
<li>Rarely iatrogenic from malposition or migration of endovascular
aortic stent grafts over the renal orifices.</li>
</ul></li>
</ol>
<p><img src="images/renal1.png" width="468" /></p>
<!--# Needs a reference -->
<p><strong>I think the flow limitation part has been well established. What
next?</strong></p>
<p>Renal (especially bilateral) hypoperfusion induces activation of the
renin-angiotensin-aldosterone system which increases vascular tone and
impairs sodium excretion resulting in expansion of the extracellular
fluid volume.</p>
</div>
<div id="medical-management-and-evaluation" class="section level2" number="7.2">
<h2><span class="header-section-number">7.2</span> Medical Management and Evaluation</h2>
<p><strong>Can’t we just treat their hypertension and give these patients an ACE
inhibitor at this point?</strong></p>
<p>Sure. And oftentimes we do. In fact, many of these patients can be
treated with medical therapy without loss of function or irreversible
fibrosis, sometimes for many years</p>
<ul>
<li><p>Studies in human subjects demonstrate that, despite a moderate
reduction in renal perfusion pressure (up to 40 %) and in renal
blood flow (mean 30 %), glomerular filtration is reduced but tissue
oxygenation within the kidney cortex and medulla can adapt without
the development of severe hypoxia.</p></li>
<li><p>But this only works to an extent.</p></li>
</ul>
<p><strong>Explain that…</strong></p>
<p>As the hypertension is treated, we’re lowering the pressure gradient
across the stenosis and can actually increase the degree of renal
malperfusion and worsen the renal function.</p>
<ul>
<li>Oftentimes this loss of kidney function is a reversible consequence
of antihypertensive therapy but it to some degree limits our ability
to control the hypertension medically without causing further damage
to the kidneys…. And it can also reflect progressive narrowing of
the renal arteries and/or progressive intrinsic kidney disease as
more advanced vascular occlusion, corresponding to a 70 to 80%
narrowing of the renal artery, leads to demonstrable cortical
hypoxia.</li>
</ul>
<p><strong>Can we tell who has cortical hypoxia through diagnostic tests?</strong></p>
<p>A: To some degree. Cortical perfusion can be measured by blood oxygen
level dependent magnetic resonance (BOLD-MR). Additionally, inflammatory
markers sampled from renal veins of stenotic kidneys correlated strongly
with the degree of hypoxia (as measured by BOLD-MR), particularly after
correction of the stenosis with angioplasty</p>
<p><strong>So we have a patient with evidence of malperfused kidneys, either
through worsening renal function or uncontrolled hypertension, with
known discrete stenoses, and we even got a BOLD-MRI which confirms it.
Let’s just revascularize them and be done with it?</strong></p>
<p>Not so fast. Although vascular stenosis or occlusion can initiate these
processes, long-standing ischemia causes parenchymal injury
characterized by inflammation and fibrosis which eventually becomes an
irreversible process. At some point, restoring renal blood flow provides
no recovery of kidney function or clinical benefit.</p>
<p><strong>So how can we determine who has CKD or hypertension due to
renovascular stenosis that we can actually help?</strong></p>
<p>This is probably the most important question since in this whole disease
process.</p>
<ul>
<li>To start, if a patient has the clinical manifestations of ischemic
nephropathy or renovascular hypertension as we discussed above, a
presumptive diagnosis of ischemic nephropathy can be made if there
is radiologic documentation of significant stenosis (usually more
than 70 % luminal occlusion) of both renal arteries or of one renal
artery to a solitary functioning kidney.</li>
</ul>
<p><strong>But how do we know the vascular occlusive disease posing critical
hemodynamic limitation to kidney function?</strong></p>
<ul>
<li><p>Generally, luminal occlusion of at least 60 to 75 % is required to
limit blood flow and reduce perfusion pressure</p></li>
<li><p>This degree of stenosis is usually associated with a measurable
translesional “pull-back” pressure gradient of 10 to 15 mmHg.</p></li>
<li><p>Doppler ultrasound criteria conventionally require peak systolic
velocities above 180 to 200 cm/sec to identify more than 60 %
luminal stenoses but identifiable levels of cortical hypoxia
(measured by blood oxygen level dependent magnetic resonance
BOLD-MR) are usually associated with translesional velocities above
385 cm/sec or reduction of single kidney glomerular filtration rate
(GFR) in the range of 20 to 25 mL/min.</p></li>
</ul>
<p><strong>Most importantly: is the condition of the kidneys such that restoring
renal blood flow is likely to benefit function?</strong></p>
<p>Short answer, we still can’t be certain.</p>
<p>Long answer, we can at least have some idea by considering the renal
resistive index, the six-month trajectory of kidney function, and the
size of the kidneys or by performing a kidney biopsy (which is not
usually done).</p>
<ul>
<li><p>None of these factors predict the outcome of revascularization with
certainty.</p></li>
<li><p><u>Improved and validated methods to evaluate the salvageability of
kidney function in this disorder are greatly needed and are the holy
grail of this disease process.</u></p></li>
</ul>
<p><strong>Let’s go through some of these:</strong></p>
<p><u>Renal Resistive index:</u></p>
<p>Some studies indicate that elevated resistive indices in segmental
vessels (above 0.80) measured by duplex ultrasound denote poor prognosis
for renal recovery while a low resistive index is a favorable sign.</p>
<p><u>Trajectory of kidney function</u></p>
<p>The most consistent predictor of good recovery of kidney function after
revascularization has been a recent deterioration of kidney function
(ie, in the prior six to twelve months).</p>
<p><u>Kidney size</u></p>
<p>Very small kidneys (less than 7 cm in longest diameter) are usually
considered unlikely to recover after revascularization.</p>
<p><u>Kidney biopsy</u></p>
<p>Previous studies suggest that biopsy demonstrating preexisting
atheroembolic changes and interstitial fibrosis indicate a limited
potential for recovery.</p>
<ul>
<li>Biopsies are not usually performed.</li>
</ul>
<p><u>Comparison of kidney morphology with kidney function</u></p>
<p>Some investigators have recommended assessing morphologic parameters,
such as renal parenchymal volume and cortical thickness with MRI, and
comparing these parameters with kidney function measured by radionuclide
scanning</p>
<ul>
<li>In a stenotic kidney, apparently normal morphology combined with
reduced function may indicate a “hibernating kidney” that could be
salvaged with revascularization.</li>
</ul>
<p><strong>So how do we get a definitive diagnosis?</strong></p>
<p>A definitive diagnosis is not usually made before revascularization. In
practice, confirmation of the diagnosis is based upon stabilization or
improvement of the GFR after successful revascularization.</p>
</div>
<div id="operative-managment" class="section level2" number="7.3">
<h2><span class="header-section-number">7.3</span> Operative Managment</h2>
<p><strong>Now we think our patient’s renal artery stenosis maybe is causing
hypertension or decline in renal function and we can possibly reverse
it… how do we treat it?</strong></p>
<p>For starters, all of these patients should receive medical therapy to
control their hypertension in addition to routine CKD care and
surveillance. They need to be aggressively treated for secondary
prevention of cardiovascular morbidity with aspirin, statins, cessation
of smoking, and, in patients with diabetes, glycemic control.</p>
<p><strong>Second, once diagnosis has been made we have 2 therapeutic
alternatives… Which are?</strong></p>
<p>First, medical therapy alone- this generally involves ACE-I or ARB and
as we discussed.</p>
<p>Hemodynamically mediated acute kidney injury is the major limitation of
ACE inhibitors and ARBs in patients with bilateral renal artery stenosis
as lowering the systemic blood pressure is more likely to reduce the
renal perfusion and thus the intraglomerular pressure below the limits
of renal autoregulation… in turn lowering the GFR.</p>
<p><strong>Okay, in other words we can have chronic normalization of the systemic
pressure that might eventually lead to ischemic atrophy due to the
reduced renal perfusion pressure distal to the stenosis? Any other
concerns with medical management alone?</strong></p>
<ul>
<li>We’re addressing or prevention progression of stenosis in those with
atherosclerotic disease.</li>
</ul>
<p><strong>Since this isn’t a vascular medicine podcast, what’s our other
option?</strong></p>
<p>Procedural intervention (open or endovascular) along with medical
therapy.</p>
<p><strong>Now you’re talking. Who should we fix operatively?</strong></p>
<p>Some but not all patients should undergo revascularization, Patient
selection single most important factor.</p>
<p>Depends upon the hemodynamic severity and likely recoverability of
kidney function</p>
<p><strong>You mentioned recoverability before, can you once again touch on what
helps us determine recoverability?</strong></p>
<ul>
<li><p>Recoverability indicators–</p>
<ul>
<li><p>A short duration of blood pressure elevation prior to the
diagnosis of renovascular disease, since this is the strongest
clinical predictor of a fall in blood pressure after renal
revascularization</p></li>
<li><p>Failure of optimal medical therapy to control the blood pressure</p></li>
<li><p>Intolerance to optimal medical therapy (eg, deterioration of
renal function during antihypertensive drug therapy)</p></li>
<li><p>Recurrent flash pulmonary edema and/or refractory heart failure</p></li>
<li><p>Otherwise unexplained progressive renal insufficiency,
particularly if proteinuria is absent</p></li>
</ul></li>
</ul>
<p><strong>But do we have any good data proving our interventions help?</strong></p>
<p>This is where things can get muddy.</p>
<p>Early on, observational studies demonstrated a high rate of procedural
success with percutaneous transluminal renal angioplasty (PTRA) and
stent placement (~85%) in patients with ostial atherosclerotic disease,
as well as a high rate of clinical success measured by improvements in
blood pressure and kidney function in 50 to 75 % of subjects.</p>
<p><strong>Anything better than observational studies?</strong></p>
<p>Unfortunately, randomized trials showed no additional benefit from
stenting when added to medical therapy with respect to blood pressure
control, renal function, cardiovascular events, and mortality. But these
studies have their own limitations.</p>
<p><strong>The one we keep hearing about is the CORAL trial. Tell me about
that.</strong></p>
<ul>
<li><p>CORAL trial<span class="citation"><sup>[<a href="#ref-cooperStentingMedicalTherapy2014" role="doc-biblioref">118</a>]</sup></span></p>
<ul>
<li><p>Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)
trial</p></li>
<li><p>947 patients (80 % had unilateral disease) who met the following
two criteria:</p>
<ul>
<li><p>Unilateral or bilateral atherosclerotic renal artery
stenosis &gt;60 % if diagnosed with conventional angiography,
peak systolic velocity &gt;300 cm/second if diagnosed by duplex
Doppler ultrasonography, Luminal narrowing &gt;80 % if
diagnosed with magnetic resonance angiography or
computerized tomography angiography (or &gt;70 % with
additional evidence of renal ischemia)</p></li>
<li><p>Systolic hypertension despite two or more antihypertensive
medications and/or an estimated glomerular filtration rate
(eGFR) &lt;60 mL/min/1.73 m2 that was presumably due to the
stenosis.</p></li>
<li><p>All patients received antiplatelet therapy plus best medical
therapy including ARB</p></li>
</ul></li>
<li><p>Revascularization had no additional effect on the primary
outcome (a composite of cardiovascular or renal death, stroke,
myocardial infarction, hospitalization for heart failure, a
reduction in eGFR by more than 30 %, or end-stage renal disease)
as compared with medical therapy alone (35.1 versus 35.8 %).</p></li>
<li><p>No effect on any of the individual components of the primary
outcome.</p></li>
<li><p>Low procedural complication rate ~2%</p></li>
</ul></li>
</ul>
<p><strong>Well, that sounds pretty convincing.</strong></p>
<ul>
<li><p>Limitations on existing treatment data:</p>
<ul>
<li><p><u>Considerable selection bias</u> – For the most part, the
patients enrolled in these trials did <strong>not</strong> meet the criteria
for selecting patients likely to benefit from intervention (eg,
short duration of blood pressure elevation, hypertension
resistant to medical therapy, recurrent flash pulmonary edema):</p>
<ul>
<li><p>CORAL<span class="citation"><sup>[<a href="#ref-cooperStentingMedicalTherapy2014" role="doc-biblioref">118</a>]</sup></span></p>
<ul>
<li><p>Patients hospitalized for heart failure within 30 days
of screening for the trial were excluded, thereby
limiting the number of trial participants with recurrent
flash pulmonary edema.</p></li>
<li><p>Mean number of antihypertensive medications used by
CORAL participants at baseline was 2.1- many had not
failed optimal medical therapy</p></li>
<li><p>More than 25 % had controlled blood pressure upon entry
into the trial.</p></li>
<li><p>Mortality and event rates lower than in most previous
registries, suggesting that many high-risk patients were
not enrolled.</p></li>
</ul></li>
<li><p>ASTRAL<span class="citation"><sup>[<a href="#ref-astralinvestigatorsRevascularizationMedicalTherapy2009" role="doc-biblioref">119</a>]</sup></span></p>
<ul>
<li>Large number of patients had stenoses that were probably
not clinically significant (50 to 70 %), and patients
were excluded if their primary doctors felt that they
“definitely” needed revascularization.</li>
</ul></li>
</ul></li>
<li><p><u>Results of the trials differ substantially from observational
reports of “high-risk” subsets</u></p>
<ul>
<li>For the most part, patients selected by their treating
clinicians to undergo revascularization have derived greater
benefit from revascularization than did patients enrolled in
the trials who were randomly assigned to revascularization</li>
</ul></li>
</ul></li>
</ul>
<div id="endovascular-therapy" class="section level3" number="7.3.1">
<h3><span class="header-section-number">7.3.1</span> Endovascular Therapy</h3>
<p><strong>We’ve determined our patient is an appropriate candidate for
intervention, and we don’t fully buy into CORAL, what can we do?</strong></p>
<ul>
<li><p><u>Percutaneous renal angioplasty/stenting</u>in addition to medical
therapy</p>
<ul>
<li><p>Most commonly employed if technically feasible.</p></li>
<li><p>Most amenable lesions to angioplasty are those producing
incomplete occlusion in the main renal artery.</p>
<ul>
<li>Total occlusions and ostial lesions extending into aorta
generally do not respond well to angioplasty alone due to
elastic recoil.</li>
</ul></li>
<li><p>Quick results: maximum antihypertensive response is generally
observed at 48 hours after the procedure</p>
<ul>
<li>But BP levels and antihypertensive drug requirements often
change over subsequent weeks</li>
</ul></li>
<li><p>In general, the effects of revascularization on blood pressure
were greater in bilateral disease, but effects on renal function
and mortality did not differ in those with bilateral as compared
with unilateral stenosis .</p></li>
<li><p>Most atherosclerotic lesions are now treated with primary
stenting to avoid rapid development of restenosis.</p>
<ul>
<li><p>A higher initial primary success rate, defined as less than
50 % stenosis (88 versus 57 %).</p></li>
<li><p>At six months, a higher patency rate (75 versus 29 %) and a
lower restenosis rate (14 versus 48 %).</p></li>
<li><p>Twelve patients assigned to PTRA alone underwent stenting
because of treatment failure within six months. These
patients had a similar blood pressure response as those
initially treated with stenting.</p></li>
</ul></li>
</ul></li>
</ul>
<p><strong>What about complications?</strong></p>
<ul>
<li><p>Complication rate with percutaneous transluminal renal angioplasty
with or without stenting is between 5 and 15 %</p>
<ul>
<li><p>Mostly minor: puncture site hematoma and renal artery
dissection.</p></li>
<li><p>Serious complications more rare: renal artery thrombosis or
perforation, AKI 2/2 atheroembolic disease (~1%)or
radiocontrast agent injury.</p></li>
<li><p>Mortality exceedingly rare</p></li>
</ul></li>
</ul>
<p><strong>Outcomes data</strong></p>
<ul>
<li><p>In the correct patient population:</p>
<ul>
<li><p>Unilateral disease</p>
<ul>
<li><p>PTRA alone results in normalization of blood pressure
(removal of antihypertensive drug therapy) ~8-20%</p></li>
<li><p>Some improvement 50-60%</p></li>
<li><p>Failure rate ~20-30%</p></li>
<li><p>Restenosis rate of 8 to 30 % at two years (without stent)</p></li>
<li><p>Better results with unilateral fibromuscular disease.</p></li>
<li><p>Less consistent for patients with chronic hypertension
compared with patients who have an acute elevation in blood
pressure</p></li>
</ul></li>
<li><p>Bilateral disease</p>
<ul>
<li><p>25-30% will recover kidney function to a meaningful degree,
sometimes avoiding progression to end-stage kidney disease
(ESKD) and/or the need for renal replacement therapy.</p></li>
<li><p>~50% will have little immediate change in kidney function
but will “stabilize”</p></li>
<li><p>~20% will have a progressive deterioration of kidney
function, sometimes related to the procedure</p></li>
</ul></li>
</ul></li>
</ul>
<p><strong>Guidelines</strong></p>
<ul>
<li><p>2005 ACC/AHA guidelines on peripheral artery disease recommends that
a stent be placed in patients undergoing PTRA for treatment of
atherosclerotic renal artery stenosis<span class="citation"><sup>[<a href="#ref-hirschACCAHA20052006" role="doc-biblioref">120</a>]</sup></span></p>
<ul>
<li><p>PTRA without stent placement is rarely performed unless the
anatomy precludes stenting.</p></li>
<li><p>POBA without stenting is generally less successful and
associated with more complications (eg atheroemboli)</p></li>
</ul></li>
</ul>
<p><strong>How durable is PTA/stenting?</strong></p>
<ul>
<li><p>Restenosis</p>
<ul>
<li><p>~11-17%</p>
<ul>
<li>11-39% during the first one to two years</li>
</ul></li>
<li><p>Detected as a rise in blood pressure requiring more intensive
therapy</p></li>
<li><p>Angioplasty/stenting injures the vascular endothelium, which may
result in restenosis.</p></li>
<li><p>Symptomatic stenosis leading to a rise in blood pressure or a
fall in GFR are less common and are reported in 10 to 20 % of
patients</p></li>
</ul></li>
</ul>
<p><strong>How do you follow these patients after stenting?</strong></p>
<ul>
<li><p>Follow-up of patients who have had a renal artery stent should
include serial measurements of blood pressure and estimation of GFR.</p>
<ul>
<li><p>Post-stent duplex ultrasound @2-4weeks with</p></li>
<li><p>Repeated examinations on a quarterly basis (not much data)</p></li>
<li><p>Patients who develop an increase in pressure or reduced GFR
after stenting should undergo duplex ultrasonography to identify
restenosis</p></li>
<li><p>Retreatment with angioplasty with or without repeat stenting can
be attempted, but the restenosis rate after repeat angioplasty
is increased.</p>
<ul>
<li>Surgical reconstruction may be pursued in patients with
recurrent episodes of restenosis and loss of kidney
function.</li>
</ul></li>
</ul></li>
</ul>
</div>
<div id="open-surgery" class="section level3" number="7.3.2">
<h3><span class="header-section-number">7.3.2</span> Open Surgery</h3>
<p><strong>What about an open operation?</strong></p>
<ul>
<li><p><u>Surgical revascularization</u> used in addition to medical
therapy</p>
<ul>
<li>Less common since the widespread application of effective
antihypertensive drug therapy and endovascular stents (mid 90s)</li>
</ul></li>
</ul>
<p><strong>So who still gets open repair?</strong></p>
<ul>
<li>Primarily for correction of complex vascular lesions and/or repeated
episodes of in-stent restenosis</li>
</ul>
<p><strong>How do we do it?</strong></p>
<ul>
<li><p>Involves bypassing the stenotic segment or of removing a small
atrophic kidney with nearly complete arterial occlusion.</p>
<ul>
<li><p>From the aorta or hepatorenal or splenorenal bypass to avoid
diseased aorta.</p></li>
<li><p>Bilateral: either bilateral repair or unilateral repair with
contralateral nephrectomy of a nonfunctioning, atrophic kidney.</p></li>
</ul></li>
</ul>
<p><strong>How do outcomes compare to PTA/stenting?</strong></p>
<ul>
<li><p>Equally or more effective than PTRA in the treatment of
atherosclerotic disease, with cure of or improvement in the
hypertension occurring in 80 to 95 % of patients.</p>
<ul>
<li>Cure of hypertension after surgery is most likely in patients
who have been hypertensive for less than five years</li>
</ul></li>
<li><p>Lack of complete response was usually associated with one of two
factors:</p>
<ul>
<li><p>Presence of underlying primary/essential hypertension</p></li>
<li><p>Development of intrarenal vascular disease due to exposure of
the contralateral kidney to the elevated blood pressure.</p></li>
</ul></li>
</ul>
<p><strong>Guidelines recommendations?</strong></p>
<ul>
<li><p>2005 American College of Cardiology/American Heart Association
(ACC/AHA) guidelines<span class="citation"><sup>[<a href="#ref-hirschACCAHA20052006" role="doc-biblioref">120</a>]</sup></span></p>
<ul>
<li>Open surgery in patients with atherosclerotic renal artery
stenosis largely restricted to those who have multiple small
renal arteries, have early primary branching of the main renal
artery, require aortic reconstruction near the renal arteries
for other indications (eg, aneurysm repair or severe aortoiliac
occlusive disease), or to avoid manipulation of a highly
diseased aorta or failed endovascular stents (using specific
surgical techniques, including splenorenal, ileorenal, or
hepatorenal bypass procedures).</li>
</ul></li>
</ul>
<p><strong>So why not do it instead of stent?</strong></p>
<ul>
<li><p>In-hospital mortality: ~3-10 % in high volume centers</p>
<ul>
<li><p>Risk factors diffuse atherosclerosis, advanced age, chronic
kidney disease, heart failure, or chronic lung disease.</p></li>
<li><p>No deaths in 105 procedures for fibromuscular dysplasia (FMD).</p></li>
</ul></li>
</ul>
</div>
</div>
<div id="fibromuscular-dysplasia-fmd" class="section level2" number="7.4">
<h2><span class="header-section-number">7.4</span> Fibromuscular Dysplasia (FMD)</h2>
<p><strong>You mentioned FMD as a cause of renovascular hypertension, tell me
more about that…</strong></p>
<p>Fibromuscular dysplasia (FMD) is a noninflammatory, nonatherosclerotic
disorder that leads to arterial stenosis, occlusion, aneurysm,
dissection, and arterial tortuosity.</p>
<ul>
<li>Virtually always diagnosed radiographically – formerly
pathologically, but rarely sent for specimen in modern diagnosis or
treatment</li>
</ul>
<p><strong>How do we classify it?</strong></p>
<ul>
<li><p>Most commonly classified by angiographic appearance:</p>
<ul>
<li><p>Multifocal FMD (more common)</p>
<ul>
<li><p>angiographic appearance of a “string of beads.”</p></li>
<li><p>corresponds pathologically to medial fibroplasia, the most
common histologic type, and to perimedial fibroplasia, which
is less common.</p></li>
</ul></li>
<li><p>Focal FMD (less common)</p>
<ul>
<li><p>angiographic appearance of a “circumferential or tubular
stenosis”</p></li>
<li><p>corresponds pathologically to intimal fibroplasia but medial
hyperplasia and periarterial hyperplasia may also have a
focal appearance.</p></li>
</ul></li>
<li><p>These two different angiographic subtypes of FMD (multifocal and
focal) have different phenotypic presentations and natural
history</p>
<ul>
<li>Is FMD is, in fact, a single disease?</li>
</ul></li>
</ul></li>
</ul>
<p><strong>Where does it occur?</strong></p>
<ul>
<li><p>Has been observed in nearly every arterial bed</p></li>
<li><p>Involvement of the renal arteries ~75-80%</p></li>
<li><p>Involvement of the extracranial cerebrovascular arteries (eg,
carotid and vertebral arteries) ~75%</p>
<ul>
<li>2/3 of patients have multiple arteries involved.</li>
</ul></li>
</ul>
<p><strong>Who has FMD?</strong></p>
<ul>
<li><p>~90% of cases in adults are in women.</p>
<ul>
<li>No female predominance among children with FMD.</li>
</ul></li>
<li><p>Mean age at diagnosis was 52 years, with a range of 5 to 86 years</p>
<ul>
<li>In the past, it was believed that FMD was a disease of young
women. However, older now know to make up a large proportion of
affected</li>
</ul></li>
<li><p>35-50% of cases in children and 5-10% of cases in adults under the
age of 60 years with renovascular hypertension</p></li>
<li><p>Often an incidental finding:</p>
<ul>
<li><p>4.4% of potential kidney donors had evidence of FMD.</p></li>
<li><p>CORAL trial:</p>
<ul>
<li>FMD was discovered in 5.7% of the total study population
(8.8% of enrolled females)</li>
</ul></li>
</ul></li>
</ul>
<p><strong>What causes FMD?</strong></p>
<p>The etiology of FMD remains unknown, but some mechanisms have been
proposed</p>
<ul>
<li><p>Genetics may play an important role in development</p>
<ul>
<li><p>Some studies report autosomal mode of inheritance with variable
penetrance</p></li>
<li><p>Potential association with a single nucleotide variant in the
phosphatase and actin regulator 1 gene (PHACTR1)</p></li>
<li><p>Variant rs9349379 is also a risk locus for coronary artery
disease, migraine headache, and cervical artery dissection.</p></li>
</ul></li>
<li><p>Predominance of young/childbearing age women hormonal influences are
thought to play a role</p>
<ul>
<li>Remains unproven.</li>
</ul></li>
<li><p>Mechanical factors such as stretch and trauma unproven.</p></li>
</ul>
<p><strong>Does FMD present differently that the atherosclerotic renovascular
disease we talked about?</strong></p>
<ul>
<li><p>Varies widely depending on artery affected and as it results from:</p></li>
<li><p>Ischemia related to stenosis</p></li>
<li><p>Dissection and occlusion of major arteries (renal infarction,
stroke, myocardial infarction)</p></li>
<li><p>Rupture of aneurysms</p></li>
<li><p>Embolization of intravascular thrombi from dissection or aneurysms</p></li>
</ul>
<p><strong>What are the common presenting symptoms and signs</strong></p>
<ul>
<li><p>Manifestations of renal FMD (eg, hypertension, flank pain) are more
likely to occur in men, as are arterial dissections and aneurysms.</p>
<ul>
<li><p>Most common presenting signs:</p></li>
<li><p>Hypertension – 67% (66% of women and 74 % of men)</p></li>
</ul></li>
<li><p>But overall hypertension is the most common manifestation of renal
artery FMD in both genders</p>
<ul>
<li>Flank pain and abdominal pain can result from ischemia, aneurysm
rupture, or dissection of renal and mesenteric arteries,
respectively.</li>
</ul></li>
</ul>
<p><strong>Are these dissections common?</strong></p>
<ul>
<li><p>High prevalence of aneurysm and/or dissection</p>
<ul>
<li><p>Aneurysm (22%) and dissection (26%).</p>
<ul>
<li><p>34% of aneurysms were renal</p></li>
<li><p>11% of dissections were renal</p></li>
</ul></li>
<li><p>42% had an aneurysm and/or dissection.</p></li>
</ul></li>
</ul>
<p><strong>So should we screen for these dissections in a patient with known
FMD?</strong></p>
<ul>
<li><p>Every patient diagnosed with FMD should have one-time,
head-to-pelvic CTA (or MRA) is an alternative.</p>
<ul>
<li>CTA of the neck and head on one day followed one week later by
CTA of the chest, abdomen, and pelvis</li>
</ul></li>
</ul>
<p><strong>When should we suspect FMD?</strong></p>
<ul>
<li><p>Hypertension (particularly in a woman under the age of 60 years)
with findings that would prompt an evaluation for secondary
hypertension:</p>
<ul>
<li><p>Severe or resistant hypertension.</p></li>
<li><p>Onset of hypertension before the age of 35 years.</p></li>
<li><p>A sudden rise in blood pressure over a previously stable
baseline.</p></li>
<li><p>A significant increase in the serum creatinine concentration
after the institution of therapy with an angiotensin-converting
enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) in
the absence of an excessive reduction in blood pressure.</p></li>
<li><p>An epigastric/abdominal bruit.</p></li>
</ul></li>
<li><p>Renal artery dissection (or carotid, vertebral, coronary)</p></li>
<li><p>Aneurysm in a visceral, carotid, vertebral, or intracranial vessel.</p></li>
<li><p>Renal infarction.</p></li>
</ul>
<p><strong>How do we diagnose this and/or distinguish it from renovascular
atherosclerotic disease?</strong></p>
<ul>
<li><p>Confirmed by diagnostic imaging that reveals consistent findings</p></li>
<li><p>Noninvasive imaging test is usually performed first. This includes
CTA, MRA, and Duplex ultrasound.</p></li>
</ul>
<p><strong>Let talk about CTA…</strong></p>
<ul>
<li><p>CTA is preferable due to higher spatial resolution than MRA, less
dependence upon technical expertise, and a shorter scan time</p></li>
<li><p>Excellent diagnostic accuracy for FMD of the main renal arteries,
although the sensitivity decreases when FMD is only present in the
smaller branch renal arteries.</p></li>
<li><p>Multirow detector CT scanners, which offer more rapid image
acquisition, variable section thickness, three-dimensional
rendering, diminished helical artifacts, and smaller contrast
requirements, may gain an increased role in the diagnosis and
follow-up of renal artery FMD</p></li>
</ul>
<p><strong>What about MRA?</strong></p>
<ul>
<li><p>Inconsistent detection of FMD and is performed if CTA is
contraindicated</p></li>
<li><p>The spatial resolution in the branch vessels is not adequate, and
artifact may occur, suggesting “beading” when none is present.</p></li>
<li><p>May miss mild FMD.</p></li>
<li><p>Can be useful for detecting aneurysms and dissections</p></li>
</ul>
<p><strong>And finally, Duplex ultrasonography</strong></p>
<ul>
<li><p>Detects elevated blood flow velocities in the mid and distal
portions of the renal artery, most common locations for FMD.</p></li>
<li><p>Increased peak systolic velocity, turbulent blood flow, and
tortuosity of the mid and distal artery.</p>
<ul>
<li>% diameter stenosis reports less helpful and usually inaccurate</li>
</ul></li>
<li><p>lowest spatial resolution of all of the cross-sectional imaging
modalities</p></li>
<li><p>most operator dependence</p></li>
<li><p>first choice only in high-volume centers with extensive expertise in
this technique</p></li>
</ul>
<p><strong>What about non invasive testing?</strong></p>
<ul>
<li><p>DSA is performed in patients if there is a high clinical suspicion
of FMD, and treatment with revascularization is planned if a
stenosis is found.</p>
<ul>
<li><p>Can improve visualization of the arteries by eliminating
background soft tissue and bone and has higher spatial
resolution than any of the other imaging modalities</p></li>
<li><p>Can measure the pressure gradient across the stenosis</p>
<ul>
<li><p>Pressure decrease threshold of 10 % or more of the mean
pressure should be used to decide whether a lesion is
hemodynamically significant</p></li>
<li><p>IVUS and optical coherence tomography (OCT) can be helpful
in determining if a dissection or intramural hematoma is
present as well as help to determine if angioplasty has
improved the stenosis.</p></li>
</ul></li>
<li><p>Negative DSA excludes a diagnosis of FMD in the vascular bed
that was imaged.</p></li>
</ul></li>
</ul>
<p><strong>Any place for pathologic diagnosis in modern therapy?</strong></p>
<ul>
<li><p>Histopathology (and histologic classification) is <strong>no longer</strong> part
of the diagnosis.</p>
<ul>
<li>Only in the rare patient who requires surgical revascularization
or resection of an aneurysm.</li>
</ul></li>
</ul>
<p><strong>So how do we treat this, what warrants intervention and are those
interventions different than what we offer atherosclerotic disease of
the renal arteries?</strong></p>
<ul>
<li><p>All patients with FMD should be placed on antiplatelet therapy (ASA)
unless otherwise contraindicated</p></li>
<li><p><u>Antihypertensive therapy</u></p>
<ul>
<li><p>Most patients will require antihypertensive therapy, even if
they undergo revascularization.</p></li>
<li><p>Majority of patients with <strong>focal</strong> FMD have their blood
pressure cured with angoplasty</p></li>
</ul></li>
</ul>
<p><strong>But what about revascularization?</strong></p>
<ul>
<li><p><u>Revascularization</u> Goal: control of hypertension</p>
<ul>
<li><p>BP can be controlled in most adults with multifocal FMD with a
mean of two antihypertensive medications</p></li>
<li><p>Weigh risks and benefits in well controlled hypertension.</p></li>
</ul></li>
<li><p><strong>No</strong> randomized trials comparing revascularization with medical
therapy</p></li>
</ul>
<p><strong>Well then who do we treat?</strong></p>
<ul>
<li><p>Recent-onset hypertension, with goal to cure hypertension.</p></li>
<li><p>Resistant hypertension despite compliance with an appropriate
three-drug regimen.</p></li>
<li><p>Patients unable to tolerate antihypertensive medications or who are
noncompliant with their medication regimen.</p></li>
<li><p>Adults with bilateral renal FMD, or unilateral renal FMD to a single
functioning kidney, and unexplained progressive renal insufficiency
thought to result from renal artery stenosis</p></li>
<li><p>Hypertensive children.</p></li>
<li><p>may be at higher risk than adults for progressive renal parenchymal
loss, and therefore could benefit from revascularization even if
their hypertension can be well-controlled with one or two
antihypertensive medications.</p></li>
</ul>
<p><strong>And what kind of results do we get with revascularization?</strong></p>
<ul>
<li><p>Hypertension is cured or improved following revascularization in a
large proportion of patients with FMD.</p>
<ul>
<li><p>Much better than 2/2 atherosclerosis</p></li>
<li><p>Varies considerably from study to study, although hypertension
control improves in most patients and depends in large part upon
the definition of cure.</p></li>
<li><p>Not good data on stabilization of either GFR or renal size in
patients with FMD.</p></li>
</ul></li>
</ul>
<p>What options do we have in terms of revascularization?</p>
<p><strong>Angioplasty and open surgery</strong></p>
<p>Do we have good results treating FMD with these?</p>
<ul>
<li><p>Improvement in blood pressure (including those with and without
cure) was similar with PTA as compared with surgery (86 versus 88
%).</p></li>
<li><p>Older age and longer duration of hypertension prior to
revascularization were significantly associated with a lower cure
rate.</p></li>
</ul>
<p><strong>How do these compare?</strong></p>
<ul>
<li><p>PTA achieves similar technical success and is associated with a
lower risk of adverse events in observational studies</p></li>
<li><p>Most patients with FMD who are selected for renal revascularization
have PTA rather than surgery</p></li>
<li><p>Major adverse events were more frequent with surgery (15 versus 6
%).</p></li>
</ul>
<p><strong>So why choose open surgery?</strong></p>
<ul>
<li><p>Cure rates were higher with surgery (54 versus 36 %).</p></li>
<li><p>Surgery rather than PTA if PTA fails or if the arterial anatomy is
not amenable to PTA</p>
<ul>
<li>Patients with small renal arteries (&lt;4 mm), with branch renal
artery disease, or with extensive intimal fibroplasia.</li>
</ul></li>
</ul>
<p><strong>So how do we perform Percutaneous transluminal angioplasty</strong> for FMD?</p>
<ul>
<li><u>Without</u> stent placement… unlike PTA for atherosclerotic RAS</li>
</ul>
<p><strong>Why not place a stent?</strong></p>
<ul>
<li><p>Patients do very well with angioplasty alone, no reason to place a
stent.</p>
<ul>
<li><p>Lesion is so fibrotic that the pressure gradient cannot be
obliterated with an angioplasty, a stent will not correct this
problem</p>
<ul>
<li>Such patients should be referred for surgery.</li>
</ul></li>
</ul></li>
<li><p>Usually have stenoses in the mid and distal portions of the artery
rather than at the ostium or proximal portion (as occurs with
atherosclerosis).</p>
<ul>
<li>Should surgical revascularization become necessary due, for
example, to in-stent restenosis, patients may require more
complex branch repair to bypass the occluded stent since the
stent often covers the renal artery up to the point of the first
intrarenal branch.</li>
</ul></li>
</ul>
<p><strong>Do we ever place stents?</strong></p>
<ul>
<li>Stents placed when a dissection results from the performance of PTA
or in the rare instance in which a perforation of the renal artery
occurs during angioplasty.</li>
</ul>
<p><strong>And we’re getting good outcomes with PTA alone?</strong></p>
<ul>
<li><p>Technical (angiographic) success rates for PTA 83-100</p></li>
<li><p>Rate of restenosis 12-34% over follow-up intervals of six months to
two years</p>
<ul>
<li><p>Difficult to determine if patients with FMD develop restenosis,
or if the lesion was not completely treated correctly the first
time.</p></li>
<li><p>Not necessarily associated with recurrent hypertension.</p></li>
</ul></li>
</ul>
<p><strong>But generally we can achieve significant and sustained reductions in
systolic blood pressure, diastolic blood pressure, serum creatinine, and
number of antihypertensive agents.</strong></p>
<ul>
<li>Systolic blood pressure response was better in patients with FMD
affecting the main renal artery than in patients with branch vessel
involvement.</li>
</ul>
<p><strong>Any specific technical tips?</strong></p>
<ul>
<li><p>Cutting balloon angioplasty should be avoided</p>
<ul>
<li>Increased risk of rupture</li>
</ul></li>
<li><p>Post angioplasty visual inspection alone is <strong>not</strong> accurate.</p>
<ul>
<li><p>Measure pressure differential using a pressure guidewire, with a
mean gradient of &lt;5 mmHg across the treated segment suggesting
a satisfactory result</p>
<ul>
<li>Measure before and after angioplasty</li>
</ul></li>
<li><p>Post-procedure renal duplex scanning</p>
<ul>
<li>Degree of turbulence is less prominent, and velocity
elevation in the mid-distal renal artery returns to normal.</li>
</ul></li>
<li><p>Intravascular ultrasound or optical coherence tomography (OCT)
is occasionally used to evaluate the elimination or reduction of
various endoluminal defects.</p></li>
</ul></li>
</ul>
<p><strong>What should we do if it doesn’t work?</strong></p>
<ul>
<li><p>If either has no improvement in blood pressure or an initial
improvement followed by recurrence, repeat angiogram and PTA.</p>
<ul>
<li>Restenosis may actually represent inadequate angioplasty during
the first procedure</li>
</ul></li>
<li><p>Persistent HTN despite technically successful PTA suggests that the
cause of hypertension is unrelated to fibromuscular disease or is
related to small vessel disease within the kidney (nephrosclerosis)
due to longstanding hypertension.</p></li>
</ul>
<p><strong>What kind of complications do we see after this?</strong></p>
<ul>
<li><p>Mostly related to vascular access</p></li>
<li><p>Rarely: renal artery perforation, dissection, or segmental renal
infarction may occur.</p></li>
<li><p>Decreasing over time- 16 % in 1998 to 3 % in 2001</p></li>
</ul>
<p><strong>Ok, lets switch gears to open revascularization?</strong></p>
<ul>
<li><p>Aortorenal bypass with a saphenous vein graft is the most common
technique</p>
<ul>
<li>Artificial graft material used occasionally</li>
</ul></li>
</ul>
<p><strong>For everyone? What about for pediatric patients?</strong></p>
<ul>
<li>Pediatric patients: hypogastric artery grafts are used or else
aortic reimplantation of the renal artery is performed because vein
grafts become aneurysmal</li>
</ul>
<p><strong>How does this compare again to PTA?</strong></p>
<ul>
<li><p>Similar success rates compared to PTA (82-89% patency) but with
higher morbidity.</p>
<ul>
<li><p>Perioperative mortality appears to be very low (~1.2%)</p></li>
<li><p>Usually limited to complex cases so success and complication
would probably be higher if simpler cases were included.</p></li>
</ul></li>
</ul>
<p><strong>What’s Monitoring and follow-up look like for these patients?</strong></p>
<ul>
<li><p>Medical management only:</p>
<ul>
<li><p>Renal artery stenosis and kidney dysfunction may progress
despite good blood pressure control</p>
<ul>
<li>Mostly in patients with focal FMD and intimal fibroplasia</li>
</ul></li>
<li><p>Every patient with FMD should have measurement of serum
creatinine and renal artery duplex ultrasound every 12 months.</p></li>
</ul></li>
</ul>
<p><strong>And After revascularization</strong>?</p>
<ul>
<li><p>Duplex ultrasonography and serum creatinine measurements performed
on the first office visit post procedure, then every six months for
two years, and then yearly, if stable.</p></li>
<li><p>With worsening on new hypertension, or unexplained increase in the
serum creatinine, he or she should be imaged at that time with
duplex ultrasound (or CTA if the ultrasound is equivocal or poor
quality).</p></li>
</ul>
</div>
<div id="renal-artery-aneurysms" class="section level2" number="7.5">
<h2><span class="header-section-number">7.5</span> Renal Artery Aneurysms</h2>
<p><strong>Ok, that’s a pretty good review, but let’s switch gears and talk about
renal artery aneurysms</strong></p>
<ul>
<li><p>Renal artery aneurysms are rare.</p>
<ul>
<li><p>Autopsy studies have revealed an incidence of 0.01% to 0.09%.</p></li>
<li><p>Renal artery aneurysms are bilateral in about 10% of cases with
more than 90% of true renal artery aneurysms being
extraparenchymal.</p></li>
</ul></li>
<li><p>Females &gt; males</p>
<ul>
<li>Females and males equal with FMD excluded</li>
</ul></li>
<li><p>Most frequent site of involvement is primary bifurcation,
intraparenchymal (&lt;10%)</p></li>
<li><p>Most are saccular</p></li>
<li><p>Right slightly more common than left, bilateral 10%</p></li>
<li><p>Size criteria currently controversial*</p>
<ul>
<li><p>2.5 common criteria for visceral arterial intervention, but
paucity of data suggesting rupture risk drastically increases at
this size</p></li>
<li><p>Many aneurysms with circumferential calcification which could
offer protection against rupture</p></li>
</ul></li>
<li><p>The majority of renal artery aneurysms are asymptomatic, and less
than 3% rupture.</p>
<ul>
<li><p>Present with flank pain, hypotension</p></li>
<li><p>10% mortality</p></li>
<li><p>90% risk of kidney loss</p></li>
</ul></li>
<li><p>Although arteriosclerotic changes have been identified in most
aneurysms in patients with multiple lesions, this is not a uniform
finding, suggesting that arteriosclerosis may not be the most
important factor in the genesis of renal artery aneurysms.</p></li>
<li><p>More likely due to a congenital medial degenerative process with
weakness of the elastic lamina.</p></li>
<li><p>Fibromuscular dysplasia (FMD) is often a direct contributor to the
development of an aneurysm.</p>
<ul>
<li><p>Medial fibroplasia is typically associated with multiple
stenoses and post-stenotic dilatation of the distal two thirds
of the renal artery.</p></li>
<li><p>Renal artery aneurysms in association with FMD are generally
only a few millimeters in diameter.</p></li>
<li><p>The typical angiographic appearance of a renal artery involved
with medial fibroplasia is a “string of beads.”</p></li>
</ul></li>
<li><p>The majority of renal artery aneurysms are saccular.</p></li>
<li><p>A rare cause of renal artery aneurysms is Ehlers-Danlos’ syndrome.</p>
<ul>
<li>This disorder is associated with extreme arterial fragility and
spontaneous rupture.</li>
</ul></li>
<li><p>Renal artery dissection caused by guide wires or catheters can
occur, but is rare.</p></li>
<li><p>In an elderly patient, observation of this aneurysm with Duplex
surveillance is the appropriate treatment.</p></li>
<li><p>For larger aneurysms in younger patients, aneurysmorrhaphy with
primary repair or patching can be performed with low mortality.</p>
<ul>
<li>Endovascular techniques such as coiling have been reported to be
successful in treating these saccular aneurysms; however,
covered stent placement may be difficult in the distal renal
artery near potential branch points of the artery.</li>
</ul></li>
</ul>

</div>
</div>
<h3>References</h3>
<div id="refs" class="references csl-bib-body hanging-indent" line-spacing="2">
<div id="ref-cooperStentingMedicalTherapy2014" class="csl-entry">
118. Cooper, C. J., Murphy, T. P., Cutlip, D. E., Jamerson, K., Henrich, W., Reid, D. M., Cohen, D. J., Matsumoto, A. H., Steffes, M., Jaff, M. R., Prince, M. R., Lewis, E. F., Tuttle, K. R., Shapiro, J. I., Rundback, J. H., Massaro, J. M., D’Agostino, R. B., &amp; Dworkin, L. D. (2014). Stenting and <span>Medical Therapy</span> for <span>Atherosclerotic Renal-Artery Stenosis</span>. <em>New England Journal of Medicine</em>, <em>370</em>(1), 13–22. <a href="https://doi.org/10.1056/NEJMoa1310753">https://doi.org/10.1056/NEJMoa1310753</a>
</div>
<div id="ref-astralinvestigatorsRevascularizationMedicalTherapy2009" class="csl-entry">
119. Investigators, A. (2009). Revascularization versus <span>Medical Therapy</span> for <span>Renal-Artery Stenosis</span>. <em>The New England Journal of Medicine</em>, 10.
</div>
<div id="ref-hirschACCAHA20052006" class="csl-entry">
120. Hirsch, A. T., Haskal, Z. J., Hertzer, N. R., Bakal, C. W., Creager, M. A., Halperin, J. L., Hiratzka, L. F., Murphy, W. R. C., Olin, J. W., Puschett, J. B., Rosenfield, K. A., Sacks, D., Stanley, J. C., Taylor, L. M., White, C. J., White, J., &amp; White, R. A. (2006). <span>ACC</span>/<span>AHA</span> 2005 <span>Practice Guidelines</span> for the <span>Management</span> of <span>Patients With Peripheral Arterial Disease</span> (<span>Lower Extremity</span>, <span>Renal</span>, <span>Mesenteric</span>, and <span>Abdominal Aortic</span>): <span>A Collaborative Report</span> from the <span>American Association</span> for <span>Vascular Surgery</span>/<span>Society</span> for <span>Vascular Surgery</span>,* <span>Society</span> for <span>Cardiovascular Angiography</span> and <span>Interventions</span>, <span>Society</span> for <span>Vascular Medicine</span> and <span>Biology</span>, <span>Society</span> of <span>Interventional Radiology</span>, and the <span>ACC</span>/<span>AHA Task Force</span> on <span>Practice Guidelines</span> (<span>Writing Committee</span> to <span>Develop Guidelines</span> for the <span>Management</span> of <span>Patients With Peripheral Arterial Disease</span>): <span>Endorsed</span> by the <span>American Association</span> of <span>Cardiovascular</span> and <span>Pulmonary Rehabilitation</span>; <span>National Heart</span>, <span>Lung</span>, and <span>Blood Institute</span>; <span>Society</span> for <span>Vascular Nursing</span>; <span>TransAtlantic Inter-Society Consensus</span>; and <span>Vascular Disease Foundation</span>. <em>Circulation</em>, <em>113</em>(11). <a href="https://doi.org/10.1161/CIRCULATIONAHA.106.174526">https://doi.org/10.1161/CIRCULATIONAHA.106.174526</a>
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="mesenteric-disease.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="thoracic-aorta.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"whatsapp": false,
"all": ["facebook", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": "https://github.com/adam-mdmph/VS-Board-Review/blob/main/06-renal.Rmd",
"text": "Edit"
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": ["_main.pdf"],
"search": {
"engine": "fuse",
"options": null
},
"toc": {
"collapse": "section",
"scroll_highlight": true
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    var src = "true";
    if (src === "" || src === "true") src = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML";
    if (location.protocol !== "file:")
      if (/^https?:/.test(src))
        src = src.replace(/^https?:/, '');
    script.src = src;
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
